<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To analyze the prevalence of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> subtypes in Shanxi according to the latest World Health Organization (WHO) classification, and to compare the figures with those in other parts of the world </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The <z:chebi fb="1" ids="51686">hematoxylin</z:chebi> and eosin-stained sections of 447 <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cases from the archive files of Shanxi <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> Hospital were reviewed </plain></SENT>
<SENT sid="2" pm="."><plain>Immunohistochemical study was performed using a panel of antibodies, including ALK1, bcl-6, CD (1a, 3, 4, 5, 7, 8, 10, 15, 20, 23, 30, 43, 56, 68, 79a and 99), cyclin D1, EMA, IgD, kappa, lambda, LMP1, PAX5, TdT and Vs38C </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, in-situ hybridization for Epstein-Barr virus-encoded <z:chebi fb="40" ids="33697">RNA</z:chebi> (EBER) was carried out </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> cases were then reclassified according to the latest WHO classification of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Of the 447 cases studied, 385 cases (86.1%) were confirmed to be non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), while 62 cases (13.9%) belonged to classic Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) </plain></SENT>
<SENT sid="6" pm="."><plain>Of the NHL cases, 68.3% were of B-cell lineage and 30.6% were of T and/or NK-cell lineage </plain></SENT>
<SENT sid="7" pm="."><plain>Histiocytic <z:hpo ids='HP_0002664'>neoplasm</z:hpo> accounted for only 0.8% (3 cases) </plain></SENT>
<SENT sid="8" pm="."><plain>As for the subtyping of NHL, diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was commonest (35.1%), followed by peripheral T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, NOS (12.0%), extranodal marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (MALT <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) (11.7%), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (8.6%), T-lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (7.0%), anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (4.2%), B-small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (3.6%) and mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (2.6%) </plain></SENT>
<SENT sid="9" pm="."><plain>Amongst the 263 cases of B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 105 cases (39.9%) expressed immunoglobulin light chain (kappa in 52 cases and lambda in 53 cases) in paraffin sections </plain></SENT>
<SENT sid="10" pm="."><plain>Regarding markers for EB <z:e sem="disease" ids="C0042769" disease_type="Disease or Syndrome" abbrv="">virus infection</z:e>, 14 cases of the B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> gave positive findings with both EBER in-situ hybridization and LMP-1 immunohistochemistry, while 6 of the T/NK-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> expressed LMP-1 and 19 showed positive signals for EBER </plain></SENT>
<SENT sid="11" pm="."><plain>In NHL, there was discordance in EBER in-situ hybridization and LMP-1 immunohistochemical results </plain></SENT>
<SENT sid="12" pm="."><plain>As for <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>, EB virus positivity was noted in 37 of the 62 cases (59.7%), including 7 cases of lymphocyte-rich <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>, 11 cases of mixed cellularity <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> and 19 cases of nodular <z:mp ids='MP_0000612'>sclerosis</z:mp> <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>In classic <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>, there was complete concordance of results by both EBER in-situ hybridization and LMP-1 immunohistochemistry </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: The prevalence of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in Shanxi is similar to that in America, Australia, Japan and Korea </plain></SENT>
<SENT sid="15" pm="."><plain>The incidence of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> however is much lower than America and Australia </plain></SENT>
</text></document>